Congenital Pulmonary Airway Malformation

Complex MONDO:0016580 Pathograph 7 Respiratory Disease Congenital Anomaly

Congenital pulmonary airway malformation (CPAM), formerly congenital cystic adenomatoid malformation (CCAM), is a developmental anomaly of the lower respiratory tract characterized by a hamartomatous, predominantly cystic overgrowth of terminal bronchiolar/alveolar structures with disorganized airway branching. Lesions are classically grouped into Stocker types 0 to 4 on the basis of cyst size, histologic composition, and the presumed level of the tracheobronchial tree at which the malformation arose. Most cases are detected prenatally on routine obstetric ultrasound; many fetuses remain asymptomatic, with stable or regressing lesions, while a minority develop hydrops fetalis from mass effect and require fetal intervention. After birth, lesions may present with respiratory distress, recurrent pulmonary infections, or pneumothorax, or remain incidental on imaging. Surgical resection (most commonly anatomic lobectomy, increasingly via video-assisted thoracoscopic surgery) is the standard definitive treatment, particularly for symptomatic disease and for lesions with overlap to pleuropulmonary blastoma (former CPAM type 4).

Ask OpenScientist

Ask a research question about Congenital Pulmonary Airway Malformation. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
3
Histopath.
6
Phenotypes
7
Pathograph
2
Genes
6
Treatments
5
Subtypes
1
Deep Research
◆

Subtypes

5
Type 0 (Acinar Dysplasia)
Rare, lethal malformation of presumed tracheal/bronchial origin with acinar dysplasia involving all lobes. Now recognized as congenital acinar dysplasia and associated with germline variants.
Show evidence (1 reference)
PMID:37334833 SUPPORT Human Clinical
"germline variants in congenital acinar dysplasia, formerly CPAM type 0"
The reconsideration of the Stocker classification recognizes acinar dysplasia (former CPAM type 0) as driven by germline variants.
Type 1 (Large-Cyst, Bronchial/Bronchiolar Origin)
The most common postnatal subtype, characterized by one or a few large cysts (often >2 cm) lined by pseudostratified ciliated columnar epithelium, presumed proximal bronchial/bronchiolar origin. Frequently harbors somatic KRAS mutations and is the subtype most associated with overt malignant progression to well-differentiated mucinous adenocarcinoma.
Show evidence (2 references)
PMID:40473982 SUPPORT Human Clinical
"CPAM type 1 was found in 50%, type 2 in 22%, and type 3 in 6%."
In a contemporary 46-lesion molecular series, CPAM type 1 was the most common subtype.
PMID:37334833 SUPPORT Human Clinical
"The potential for overt malignant progression exists in the case of PPB type I and CPAM type 1 in some cases to well-differentiated mucinous adenocarcinoma."
Dehner et al. note the established potential of CPAM type 1 to progress to mucinous adenocarcinoma.
Type 2 (Small-Cyst, Bronchiolar Origin)
Multiple small uniform cysts (<2 cm) of bronchiolar origin, now widely viewed as an acquired lesion secondary to bronchial atresia. Histologic features overlap with extralobar sequestration. Associated with other congenital anomalies in classic descriptions.
Show evidence (1 reference)
PMID:37334833 SUPPORT Human Clinical
"CPAM type 2 is an acquired lesion resulting from interruption in lung development secondary to bronchial atresia."
The Stocker reconsideration reframes type 2 as a secondary lesion driven by bronchial atresia.
Type 3 (Solid/Microcystic, Acinar/Bronchiolar Origin)
Bulky, predominantly solid or microcystic lesions of distal acinar origin that often involve an entire lobe and may cause mediastinal shift and fetal hydrops.
Show evidence (1 reference)
PMID:37334833 PARTIAL Human Clinical
"mutational events either at the somatic level in KRAS (CPAM types 1 and possibly 3)"
KRAS somatic alterations may underlie CPAM types 1 and possibly 3.
Type 4 (Cystic Pleuropulmonary Blastoma Spectrum)
Large peripheral cysts of distal acinar origin lined by flattened alveolar-type epithelium. Type 4 lesions are histologically and clinically overlapping with cystic (type I) pleuropulmonary blastoma (PPB) and warrant pathological and DICER1-focused assessment.
Show evidence (1 reference)
PMID:37334833 SUPPORT Human Clinical
"pleuropulmonary blastoma (PPB), type I, formerly CPAM type 4"
The Stocker reconsideration explicitly equates former CPAM type 4 with cystic (type I) PPB.
⚙

Pathophysiology

7
Disordered Airway Branching Morphogenesis
CPAM arises from a localized disruption of airway branching morphogenesis during fetal lung development, producing a hamartomatous overgrowth of terminal bronchiolar/airway structures with cystic dilatation. The presumed level of the tracheobronchial tree at which the developmental insult occurs underlies the Stocker subtype histology, and mixed type-1/type-2 patterns support a continuum model.
epithelial cell of lower respiratory tract link
epithelial tube branching involved in lung morphogenesis link ⚠ ABNORMAL lung development link ⚠ ABNORMAL
lung link
Show evidence (2 references)
PMID:37334833 SUPPORT Human Clinical
"The developmental model of CPAM histogenesis by Stocker proposed perturbations designated as CPAM type 0 to type 4 without known or specific pathogenetic mechanisms along the airway from the bronchus to the alveolus."
Stocker's developmental model frames CPAM as level-dependent perturbations along the developing airway.
PMID:40473982 SUPPORT Human Clinical
"The presence of mixed-type patterns supports the hypothesis that CPAM represents a continuum of developmental disturbances occurring at various stages of lung branching morphogenesis."
Mixed type-1/type-2 lesions in the same specimen support a developmental-continuum model rather than discrete entities.
Bronchial Atresia and Type 2 Histology
Type 2 CPAM is increasingly interpreted as an acquired secondary lesion in which interruption of fetal airway development by bronchial atresia produces small uniform cysts of bronchiolar character. The same mechanism is invoked for the histologically similar extralobar sequestration.
epithelial cell of lower respiratory tract link
main bronchus link
Show evidence (1 reference)
PMID:37334833 SUPPORT Human Clinical
"CPAM type 2 is an acquired lesion resulting from interruption in lung development secondary to bronchial atresia. The latter is also regarded as the etiology of EIS whose pathologic features are similar, if not identical, to CPAM type 2."
The Stocker reconsideration attributes CPAM type 2 (and histologically identical extralobar sequestration) to bronchial atresia.
Somatic KRAS Mutations and Mucinous Cell Clusters
A subset of CPAM lesions, particularly type 1, harbor somatic activating KRAS mutations (commonly G12D, G12V) within foci of mucinous cell clusters. The same KRAS mutation is detected in mucinous and adjacent non-mucinous epithelium, supporting a clonal precursor lesion model within the CPAM epithelium.
pulmonary mucinous columnar cell link
KRAS link
Downstream
Progression to Mucinous Adenocarcinoma
Show evidence (4 references)
PMID:34980466 SUPPORT Human Clinical
"Subsequent genetic analysis showed somatic KRAS (Kirsten Rat Sarcoma Viral Oncogene) mutations in all three cases."
Three neonatal type 1 CPAM resections with co-existing mucinous adenocarcinoma all harbored somatic KRAS mutations.
PMID:40473982 SUPPORT Human Clinical
"Mutations were found in 24% (9 × KRAS; 2 × FGFR2). Besides classical KRAS mutations (G12D, G12V), two cases showed a double-mutation pattern (G12D/G12V; G12D/TP53)."
A 46-lesion molecular series found KRAS mutations as the predominant somatic alteration, with classical G12D/G12V codons.
PMID:40473982 SUPPORT Human Clinical
"In all MCC cases, the same mutation with comparable allele frequencies was found in mucinous and non-mucinous areas."
Concordant KRAS allele frequencies in mucinous and non-mucinous epithelium support a clonal precursor relationship.
+ 1 more reference
Progression to Mucinous Adenocarcinoma
A subset of CPAM type 1 lesions undergoes overt malignant progression to well-differentiated mucinous adenocarcinoma, the principal long-term oncologic risk recognized for CPAM. KRAS-mutant mucinous cell clusters are interpreted as the clonal precursor.
KRAS link
Show evidence (2 references)
PMID:37334833 SUPPORT Human Clinical
"The potential for overt malignant progression exists in the case of PPB type I and CPAM type 1 in some cases to well-differentiated mucinous adenocarcinoma."
Dehner et al. note the established potential of CPAM type 1 to progress to mucinous adenocarcinoma.
PMID:34980466 SUPPORT Human Clinical
"between type 1 CPAM and mucinous adenocarcinoma with KRAS point mutations"
A neonatal case series demonstrates a direct association between type 1 CPAM, mucinous adenocarcinoma, and KRAS point mutations.
DICER1-Driven Pleuropulmonary Blastoma Overlap
Lesions historically classified as CPAM type 4 overlap clinically and radiographically with cystic (type I) pleuropulmonary blastoma (PPB), a DICER1 syndrome-associated tumor of mesenchymal origin. Accurate distinction is critical because PPB requires oncologic management and DICER1 surveillance.
DICER1 link
Show evidence (2 references)
PMID:42012654 SUPPORT Human Clinical
"the purely cystic type I represents a particular diagnostic challenge. In imaging, it is often difficult to distinguish from benign congenital lung malformations such as congenital pulmonary airway malformation (CPAM, formerly congenital cystic adenomatoid malformation or CCAM), sequestration,..."
Cystic type I PPB and CPAM overlap radiographically, supporting the need for careful differentiation.
PMID:42012654 SUPPORT Human Clinical
"histopathology and genetics-especially DICER1 mutation-in the diagnosis and therapeutic decision-making of pleuropulmonary blastoma."
DICER1 mutation analysis is central to distinguishing PPB from CPAM and to guiding therapy and surveillance.
Intrathoracic Mass Effect
Large CPAM lesions produce intrathoracic mass effect, compressing adjacent lung and mediastinal structures. Severe mass effect underlies the principal indications for fetal intervention in macrocystic CPAM.
lung link
Downstream
Fetal Hydrops from Cardiac Compression
Show evidence (1 reference)
PMID:41545807 SUPPORT Human Clinical
"fetal microcystic CPAM cases with CVR > 2.0, complicated by fetal hydrops, and refractory to maternal steroid therapy"
Large CPAMs (CVR > 2.0) are clinically associated with fetal hydrops, the principal indication for fetal intervention.
Fetal Hydrops from Cardiac Compression
Severe intrathoracic mass effect from large CPAM lesions can impair venous return and cardiac output, producing fetal hydrops. Hydrops is the principal indication for fetal intervention and a major driver of perinatal mortality.
heart link
Show evidence (1 reference)
PMID:41557046 SUPPORT Human Clinical
"Fetal hydrops prior to TAS (ascites and fetal scalp oedema) was present in 36% (9/25)."
A contemporary TAS series documents fetal hydrops in 36% of severe macrocystic CPAM cases.
✶

Histopathology

3
Mucinous Cell Clusters in Type 1 CPAM
Foci of mucinous cell clusters within otherwise non-mucinous CPAM epithelium are a recognized histologic finding, particularly in type 1 lesions, and harbor KRAS mutations identical to those in adjacent non-mucinous areas.
Show evidence (1 reference)
PMID:40473982 SUPPORT Human Clinical
"Possible findings are foci of mucinous cell clusters (MCCs), harboring KRAS mutations."
Mucinous cell clusters with KRAS mutations are a recognized histologic finding in CPAM.
Mixed Type 1 and Type 2 Patterns
A substantial subset of CPAM lesions show mixed type 1 and type 2 histologic patterns within the same specimen, supporting a continuum model of developmental disturbance rather than discrete subtypes.
Show evidence (1 reference)
PMID:40473982 SUPPORT Human Clinical
"A mixed pattern of types 1 and 2 was observed in 22%."
Mixed type 1/2 histology is present in roughly one-fifth of CPAM specimens in a 46-case series.
CK7/TTF-1 Positive Epithelium
The epithelial lining of CPAM is consistently positive for CK7 and TTF-1, with variable expression of Napsin A, surfactant protein A, p40, CK5/6, and CK20 by subtype.
Show evidence (1 reference)
PMID:40473982 SUPPORT Human Clinical
"The epithelial lining was strongly positive for CK7 and TTF-1 in all samples."
Uniform CK7/TTF-1 positivity defines the lung-epithelial origin of CPAM lining.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Congenital Pulmonary Airway Malformation Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Immune 1
Recurrent Respiratory Infections Recurrent respiratory infections (HP:0002205)
Show evidence (1 reference)
PMID:40174959 SUPPORT Human Clinical
"Pneumonia was the most common symptom in congenital pulmonary airway malformation (CPAM) and intralobar sequestration, with over 30% of these patients experiencing recurrent respiratory infections."
Over 30% of adults with previously undiagnosed CPAM experience recurrent respiratory infections, supporting recurrent infection as a major phenotype.
Metabolism 1
Hydrops Fetalis Hydrops fetalis (HP:0001789)
Show evidence (1 reference)
PMID:41557046 SUPPORT Human Clinical
"Fetal hydrops prior to TAS (ascites and fetal scalp oedema) was present in 36% (9/25)."
Fetal hydrops is documented in a substantial fraction of severe macrocystic CPAM cases treated with thoracoamniotic shunting.
Respiratory 2
Respiratory Distress Respiratory distress (HP:0002098)
Show evidence (1 reference)
PMID:34980466 SUPPORT Human Clinical
"3 infants, all males, had undergone surgical resection for respiratory distress (at 3, 4 and 8 days of life)"
Neonatal respiratory distress is the indication for early surgical resection in this case series.
Pneumothorax Pneumothorax (HP:0002107)
Other 2
Congenital Pulmonary Airway Malformation Congenital pulmonary airway malformation (HP:0010959)
Show evidence (1 reference)
PMID:37334833 SUPPORT Human Clinical
"Congenital cystic pulmonary lesions (CCPLs) are represented by the following entities: congenital pulmonary airway malformation (CPAM), formerly congenital cystic adenomatoid malformation"
CPAM is defined as a congenital cystic pulmonary lesion (formerly CCAM).
Pulmonary Cyst Pulmonary cyst (HP:0032445)
Show evidence (1 reference)
PMID:42012654 SUPPORT Human Clinical
"benign congenital lung malformations such as congenital pulmonary airway malformation (CPAM, formerly congenital cystic adenomatoid malformation or CCAM)"
CPAM is classified among cystic congenital lung malformations.
🧬

Genetic Associations

2
DICER1 germline variants (former CPAM type 4 / cystic PPB overlap) (Pathogenic Variants)
Autosomal dominant
Show evidence (2 references)
PMID:37334833 SUPPORT Human Clinical
"germline variants in congenital acinar dysplasia, formerly CPAM type 0, and pleuropulmonary blastoma (PPB), type I, formerly CPAM type 4"
The Stocker reconsideration links germline variants to former CPAM types 0 and 4 (the PPB type I overlap).
PMID:42012654 SUPPORT Human Clinical
"histopathology and genetics-especially DICER1 mutation-in the diagnosis and therapeutic decision-making of pleuropulmonary blastoma."
DICER1 mutation analysis is central to distinguishing PPB from benign cystic congenital lung malformations including CPAM.
Somatic KRAS mosaic variants (CPAM types 1 and possibly 3) (Pathogenic Variants)
Show evidence (2 references)
PMID:37334833 SUPPORT Human Clinical
"mutational events either at the somatic level in KRAS (CPAM types 1 and possibly 3)"
The Stocker reconsideration assigns somatic KRAS alterations to CPAM types 1 and possibly 3.
PMID:40473982 SUPPORT Human Clinical
"Mutations were found in 24% (9 × KRAS; 2 × FGFR2). Besides classical KRAS mutations (G12D, G12V), two cases showed a double-mutation pattern (G12D/G12V; G12D/TP53)."
A 46-lesion molecular series identifies somatic KRAS G12D/G12V as the predominant alteration.
💊

Treatments

6
Anatomic Lobectomy
Action: lobectomy Ontology label: Lobectomy NCIT:C15272
Anatomic lobectomy is the most common definitive surgical treatment for CPAM in U.S. pediatric practice, used in approximately 88% of resections, and is increasingly performed via video-assisted thoracoscopic surgery (VATS), which is associated with shorter hospital stay and lower 30-day complication rates than open lobectomy.
Show evidence (2 references)
PMID:41945161 SUPPORT Human Clinical
"Lobectomy (n = 1,865; 88%) was performed far more often than sublobar resection (n = 245; 12%)"
Lobectomy was the predominant resection approach in a 10-year U.S. NSQIP-Pediatric review.
PMID:41945161 SUPPORT Human Clinical
"VATS was utilized more often than open surgery for both lobectomy (57.8%) and sublobar resections (54.7%) and was associated with lower 30-day complication rates (OR 0.58, p < 0.01) and total hospital length of stay (-1.48 days, p < 0.0001) after lobectomy."
VATS is the predominant approach for pediatric CPAM lobectomy and is associated with reduced complications and shorter hospital stays.
Sublobar Resection (Segmentectomy or Wedge)
Action: pulmonary segmentectomy Ontology label: Segmentectomy NCIT:C91061
Sublobar resection (anatomic segmentectomy or wedge resection) is a lung-sparing alternative to lobectomy for selected CPAM lesions. Anatomic segmentectomy is associated with fewer 30-day complications than lobectomy in large registry data.
Show evidence (1 reference)
PMID:41945161 SUPPORT Human Clinical
"Segmentectomy was associated with significantly fewer 30-day complications compared to lobectomy (OR 0.08, p < 0.0001)"
Anatomic segmentectomy is associated with fewer 30-day complications than lobectomy in pediatric CPAM resection.
Expectant (Conservative) Management
Action: watchful waiting Ontology label: supportive care MAXO:0000950
For asymptomatic, antenatally-diagnosed CPAMs, contemporary evidence supports observational management with serial imaging in selected patients, with low rates of serious adverse outcomes and no reported malignancy in medium-term follow-up.
Show evidence (2 references)
PMID:41643769 SUPPORT Human Clinical
"In asymptomatic patients with mainly antenatally diagnosed lesions, conservative management of CPAM lesions was associated with a complication rate and no reported cases of mortality or malignancy."
A 298-patient systematic review supports the safety of conservative management of asymptomatic CPAM with medium-term follow-up.
PMID:41643769 SUPPORT Human Clinical
"A total of 58 patients (20%) eventually underwent surgical resection due to complications, lesion progression, or parental preference."
Approximately 20% of conservatively managed asymptomatic CPAM patients ultimately undergo resection.
Fetal Thoracoamniotic Shunting
Action: surgical procedure MAXO:0000004
Thoracoamniotic shunting (TAS) is the standard fetal intervention for severe macrocystic CPAM, particularly when complicated by fetal hydrops. TAS achieves resolution of hydrops and lesion regression in the great majority of treated fetuses.
Show evidence (1 reference)
PMID:41557046 SUPPORT Human Clinical
"Resolution of hydrops and regression of the lesion occurred in 96% (24/25)."
TAS achieved resolution of hydrops and lesion regression in 96% of treated severe macrocystic CPAM fetuses.
Fetal Radiofrequency Ablation
Action: radiofrequency ablation Ontology label: Radiofrequency Ablation NCIT:C15666
For microcystic CPAM complicated by fetal hydrops and refractory to maternal steroid therapy, ultrasound-guided radiofrequency ablation (RFA) is described as a salvage intrauterine intervention, though it carries a meaningful risk of intrauterine fetal demise.
Show evidence (1 reference)
PMID:41545807 SUPPORT Human Clinical
"For microcystic CPAM complicated with fetal hydrops and refractory to maternal conservative steroid administration, ultrasound-guided RFA serves as an effective salvage option for intrauterine treatment."
Ultrasound-guided RFA is described as a salvage option for microcystic CPAM complicated by fetal hydrops refractory to steroids.
Maternal Antenatal Corticosteroids
Action: corticosteroid agent therapy MAXO:0000640
Maternal corticosteroid administration is used for large microcystic CPAM lesions to reduce mass effect and prevent or reverse fetal hydrops, with intrauterine intervention reserved for refractory cases.
Show evidence (1 reference)
PMID:41545807 SUPPORT Human Clinical
"All cases received two courses of maternal steroid before the RFA procedure."
Maternal steroid courses are standard first-line therapy for severe microcystic CPAM in this referral series.
{ }

Source YAML

click to show 
name: Congenital Pulmonary Airway Malformation
creation_date: "2026-05-13T00:00:00Z"
updated_date: "2026-05-13T19:00:00Z"
category: Complex
disease_term:
  preferred_term: congenital pulmonary airway malformation
  term:
    id: MONDO:0016580
    label: congenital pulmonary airway malformation
description: >
  Congenital pulmonary airway malformation (CPAM), formerly congenital cystic
  adenomatoid malformation (CCAM), is a developmental anomaly of the lower
  respiratory tract characterized by a hamartomatous, predominantly cystic
  overgrowth of terminal bronchiolar/alveolar structures with disorganized
  airway branching. Lesions are classically grouped into Stocker types 0 to 4
  on the basis of cyst size, histologic composition, and the presumed level
  of the tracheobronchial tree at which the malformation arose. Most cases
  are detected prenatally on routine obstetric ultrasound; many fetuses
  remain asymptomatic, with stable or regressing lesions, while a minority
  develop hydrops fetalis from mass effect and require fetal intervention.
  After birth, lesions may present with respiratory distress, recurrent
  pulmonary infections, or pneumothorax, or remain incidental on imaging.
  Surgical resection (most commonly anatomic lobectomy, increasingly via
  video-assisted thoracoscopic surgery) is the standard definitive treatment,
  particularly for symptomatic disease and for lesions with overlap to
  pleuropulmonary blastoma (former CPAM type 4).
synonyms:
- CPAM
- Congenital cystic adenomatoid malformation
- CCAM
parents:
- Respiratory Disease
- Congenital Anomaly
has_subtypes:
- name: Type 0
  display_name: Type 0 (Acinar Dysplasia)
  description: >
    Rare, lethal malformation of presumed tracheal/bronchial origin with
    acinar dysplasia involving all lobes. Now recognized as congenital
    acinar dysplasia and associated with germline variants.
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "germline variants in congenital acinar dysplasia, formerly CPAM type 0"
    explanation: The reconsideration of the Stocker classification recognizes acinar dysplasia (former CPAM type 0) as driven by germline variants.
- name: Type 1
  display_name: Type 1 (Large-Cyst, Bronchial/Bronchiolar Origin)
  description: >
    The most common postnatal subtype, characterized by one or a few large
    cysts (often >2 cm) lined by pseudostratified ciliated columnar
    epithelium, presumed proximal bronchial/bronchiolar origin. Frequently
    harbors somatic KRAS mutations and is the subtype most associated with
    overt malignant progression to well-differentiated mucinous adenocarcinoma.
  evidence:
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CPAM type 1 was found in 50%, type 2 in 22%, and type 3 in 6%."
    explanation: In a contemporary 46-lesion molecular series, CPAM type 1 was the most common subtype.
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential for overt malignant progression exists in the case of PPB type I and CPAM type 1 in some cases to well-differentiated mucinous adenocarcinoma."
    explanation: Dehner et al. note the established potential of CPAM type 1 to progress to mucinous adenocarcinoma.
- name: Type 2
  display_name: Type 2 (Small-Cyst, Bronchiolar Origin)
  description: >
    Multiple small uniform cysts (<2 cm) of bronchiolar origin, now widely
    viewed as an acquired lesion secondary to bronchial atresia. Histologic
    features overlap with extralobar sequestration. Associated with other
    congenital anomalies in classic descriptions.
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CPAM type 2 is an acquired lesion resulting from interruption in lung development secondary to bronchial atresia."
    explanation: The Stocker reconsideration reframes type 2 as a secondary lesion driven by bronchial atresia.
- name: Type 3
  display_name: Type 3 (Solid/Microcystic, Acinar/Bronchiolar Origin)
  description: >
    Bulky, predominantly solid or microcystic lesions of distal acinar
    origin that often involve an entire lobe and may cause mediastinal
    shift and fetal hydrops.
  evidence:
  - reference: PMID:37334833
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "mutational events either at the somatic level in KRAS (CPAM types 1 and possibly 3)"
    explanation: KRAS somatic alterations may underlie CPAM types 1 and possibly 3.
- name: Type 4
  display_name: Type 4 (Cystic Pleuropulmonary Blastoma Spectrum)
  description: >
    Large peripheral cysts of distal acinar origin lined by flattened
    alveolar-type epithelium. Type 4 lesions are histologically and
    clinically overlapping with cystic (type I) pleuropulmonary blastoma
    (PPB) and warrant pathological and DICER1-focused assessment.
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pleuropulmonary blastoma (PPB), type I, formerly CPAM type 4"
    explanation: The Stocker reconsideration explicitly equates former CPAM type 4 with cystic (type I) PPB.
prevalence:
- population: Europe
  percentage: 0.0106
  notes: "Estimated CPAM prevalence in Europe of approximately 1.06 per 10,000 live births."
  evidence:
  - reference: PMID:34980466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Congenital pulmonary airway malformation (CPAM) has an estimated prevalence in Europe of 1.06/10,000 live births with most being detected using maternal ultrasound screening."
    explanation: This single-center review cites the European population prevalence estimate.
- population: Global (Congenital Lung Malformations)
  percentage: 0.04
  notes: "Congenital lung malformations (including CPAM, bronchopulmonary sequestration, congenital lobar overinflation, bronchogenic cyst, and bronchial atresia) collectively occur in approximately 4 per 10,000 live births."
  evidence:
  - reference: PMID:37919294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CLMs occur in 4 out of 10,000 live births."
    explanation: The 2023 Nature Reviews Disease Primers synthesis quantifies the overall CLM birth prevalence (CPAM is the most common subtype).
pathophysiology:
- name: Disordered Airway Branching Morphogenesis
  description: >
    CPAM arises from a localized disruption of airway branching
    morphogenesis during fetal lung development, producing a hamartomatous
    overgrowth of terminal bronchiolar/airway structures with cystic
    dilatation. The presumed level of the tracheobronchial tree at which
    the developmental insult occurs underlies the Stocker subtype histology,
    and mixed type-1/type-2 patterns support a continuum model.
  cell_types:
  - preferred_term: epithelial cell of lower respiratory tract
    term:
      id: CL:0002632
      label: epithelial cell of lower respiratory tract
  biological_processes:
  - preferred_term: epithelial tube branching involved in lung morphogenesis
    term:
      id: GO:0060441
      label: epithelial tube branching involved in lung morphogenesis
    modifier: ABNORMAL
  - preferred_term: lung development
    term:
      id: GO:0030324
      label: lung development
    modifier: ABNORMAL
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The developmental model of CPAM histogenesis by Stocker proposed perturbations designated as CPAM type 0 to type 4 without known or specific pathogenetic mechanisms along the airway from the bronchus to the alveolus."
    explanation: Stocker's developmental model frames CPAM as level-dependent perturbations along the developing airway.
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The presence of mixed-type patterns supports the hypothesis that CPAM represents a continuum of developmental disturbances occurring at various stages of lung branching morphogenesis."
    explanation: Mixed type-1/type-2 lesions in the same specimen support a developmental-continuum model rather than discrete entities.
- name: Bronchial Atresia and Type 2 Histology
  description: >
    Type 2 CPAM is increasingly interpreted as an acquired secondary lesion
    in which interruption of fetal airway development by bronchial atresia
    produces small uniform cysts of bronchiolar character. The same
    mechanism is invoked for the histologically similar extralobar
    sequestration.
  cell_types:
  - preferred_term: epithelial cell of lower respiratory tract
    term:
      id: CL:0002632
      label: epithelial cell of lower respiratory tract
  locations:
  - preferred_term: main bronchus
    term:
      id: UBERON:0002182
      label: main bronchus
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CPAM type 2 is an acquired lesion resulting from interruption in lung development secondary to bronchial atresia. The latter is also regarded as the etiology of EIS whose pathologic features are similar, if not identical, to CPAM type 2."
    explanation: The Stocker reconsideration attributes CPAM type 2 (and histologically identical extralobar sequestration) to bronchial atresia.
- name: Somatic KRAS Mutations and Mucinous Cell Clusters
  description: >
    A subset of CPAM lesions, particularly type 1, harbor somatic activating
    KRAS mutations (commonly G12D, G12V) within foci of mucinous cell
    clusters. The same KRAS mutation is detected in mucinous and adjacent
    non-mucinous epithelium, supporting a clonal precursor lesion model
    within the CPAM epithelium.
  cell_types:
  - preferred_term: pulmonary mucinous columnar cell
    term:
      id: CL:0000160
      label: goblet cell
  genes:
  - preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  downstream:
  - target: Progression to Mucinous Adenocarcinoma
  evidence:
  - reference: PMID:34980466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Subsequent genetic analysis showed somatic KRAS (Kirsten Rat Sarcoma Viral Oncogene) mutations in all three cases."
    explanation: Three neonatal type 1 CPAM resections with co-existing mucinous adenocarcinoma all harbored somatic KRAS mutations.
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations were found in 24% (9 × KRAS; 2 × FGFR2). Besides classical KRAS mutations (G12D, G12V), two cases showed a double-mutation pattern (G12D/G12V; G12D/TP53)."
    explanation: A 46-lesion molecular series found KRAS mutations as the predominant somatic alteration, with classical G12D/G12V codons.
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In all MCC cases, the same mutation with comparable allele frequencies was found in mucinous and non-mucinous areas."
    explanation: Concordant KRAS allele frequencies in mucinous and non-mucinous epithelium support a clonal precursor relationship.
  - reference: PMID:37919294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "KRAS has already been confirmed to be somatically mutated in CPAM and other genetic susceptibilities linked to tumour development have been explored."
    explanation: The Nature Reviews Disease Primers synthesis affirms KRAS as a somatically mutated driver in CPAM.
- name: Progression to Mucinous Adenocarcinoma
  description: >
    A subset of CPAM type 1 lesions undergoes overt malignant progression to
    well-differentiated mucinous adenocarcinoma, the principal long-term
    oncologic risk recognized for CPAM. KRAS-mutant mucinous cell clusters
    are interpreted as the clonal precursor.
  genes:
  - preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The potential for overt malignant progression exists in the case of PPB type I and CPAM type 1 in some cases to well-differentiated mucinous adenocarcinoma."
    explanation: Dehner et al. note the established potential of CPAM type 1 to progress to mucinous adenocarcinoma.
  - reference: PMID:34980466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "between type 1 CPAM and mucinous adenocarcinoma with KRAS point mutations"
    explanation: A neonatal case series demonstrates a direct association between type 1 CPAM, mucinous adenocarcinoma, and KRAS point mutations.
- name: DICER1-Driven Pleuropulmonary Blastoma Overlap
  description: >
    Lesions historically classified as CPAM type 4 overlap clinically and
    radiographically with cystic (type I) pleuropulmonary blastoma (PPB), a
    DICER1 syndrome-associated tumor of mesenchymal origin. Accurate
    distinction is critical because PPB requires oncologic management and
    DICER1 surveillance.
  genes:
  - preferred_term: DICER1
    term:
      id: hgnc:17098
      label: DICER1
  evidence:
  - reference: PMID:42012654
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the purely cystic type I represents a particular diagnostic challenge. In imaging, it is often difficult to distinguish from benign congenital lung malformations such as congenital pulmonary airway malformation (CPAM, formerly congenital cystic adenomatoid malformation or CCAM), sequestration, or bronchogenic cyst."
    explanation: Cystic type I PPB and CPAM overlap radiographically, supporting the need for careful differentiation.
  - reference: PMID:42012654
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "histopathology and genetics-especially DICER1 mutation-in the diagnosis and therapeutic decision-making of pleuropulmonary blastoma."
    explanation: DICER1 mutation analysis is central to distinguishing PPB from CPAM and to guiding therapy and surveillance.
- name: Intrathoracic Mass Effect
  description: >
    Large CPAM lesions produce intrathoracic mass effect, compressing
    adjacent lung and mediastinal structures. Severe mass effect underlies
    the principal indications for fetal intervention in macrocystic CPAM.
  locations:
  - preferred_term: lung
    term:
      id: UBERON:0002048
      label: lung
  downstream:
  - target: Fetal Hydrops from Cardiac Compression
  evidence:
  - reference: PMID:41545807
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "fetal microcystic CPAM cases with CVR > 2.0, complicated by fetal hydrops, and refractory to maternal steroid therapy"
    explanation: Large CPAMs (CVR > 2.0) are clinically associated with fetal hydrops, the principal indication for fetal intervention.
- name: Fetal Hydrops from Cardiac Compression
  description: >
    Severe intrathoracic mass effect from large CPAM lesions can impair
    venous return and cardiac output, producing fetal hydrops. Hydrops is
    the principal indication for fetal intervention and a major driver of
    perinatal mortality.
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:41557046
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fetal hydrops prior to TAS (ascites and fetal scalp oedema) was present in 36% (9/25)."
    explanation: A contemporary TAS series documents fetal hydrops in 36% of severe macrocystic CPAM cases.
phenotypes:
- name: Congenital Pulmonary Airway Malformation
  description: The defining cystic pulmonary lesion of CPAM.
  phenotype_term:
    preferred_term: Congenital pulmonary airway malformation
    term:
      id: HP:0010959
      label: Congenital pulmonary airway malformation
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Congenital cystic pulmonary lesions (CCPLs) are represented by the following entities: congenital pulmonary airway malformation (CPAM), formerly congenital cystic adenomatoid malformation"
    explanation: CPAM is defined as a congenital cystic pulmonary lesion (formerly CCAM).
- name: Respiratory Distress
  description: >
    Symptomatic neonates present with respiratory distress driven by mass
    effect of large lesions on adjacent lung and mediastinum.
  phenotype_term:
    preferred_term: Respiratory distress
    term:
      id: HP:0002098
      label: Respiratory distress
  evidence:
  - reference: PMID:34980466
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "3 infants, all males, had undergone surgical resection for respiratory distress (at 3, 4 and 8 days of life)"
    explanation: Neonatal respiratory distress is the indication for early surgical resection in this case series.
- name: Recurrent Respiratory Infections
  description: >
    A common postnatal presentation, especially in older infants and
    children with previously undiagnosed lesions, is recurrent pulmonary
    infection localized to the affected lobe.
  phenotype_term:
    preferred_term: Recurrent respiratory infections
    term:
      id: HP:0002205
      label: Recurrent respiratory infections
  evidence:
  - reference: PMID:40174959
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Pneumonia was the most common symptom in congenital pulmonary airway malformation (CPAM) and intralobar sequestration, with over 30% of these patients experiencing recurrent respiratory infections."
    explanation: Over 30% of adults with previously undiagnosed CPAM experience recurrent respiratory infections, supporting recurrent infection as a major phenotype.
- name: Pneumothorax
  description: Spontaneous pneumothorax can complicate cystic CPAM lesions.
  phenotype_term:
    preferred_term: Pneumothorax
    term:
      id: HP:0002107
      label: Pneumothorax
- name: Hydrops Fetalis
  description: >
    Large lesions can cause mediastinal shift and cardiac compression,
    producing fetal hydrops, which is the principal indication for fetal
    intervention.
  phenotype_term:
    preferred_term: Hydrops fetalis
    term:
      id: HP:0001789
      label: Hydrops fetalis
  evidence:
  - reference: PMID:41557046
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fetal hydrops prior to TAS (ascites and fetal scalp oedema) was present in 36% (9/25)."
    explanation: Fetal hydrops is documented in a substantial fraction of severe macrocystic CPAM cases treated with thoracoamniotic shunting.
- name: Pulmonary Cyst
  description: Cystic pulmonary lesion(s) are the defining radiographic and histopathologic feature of CPAM.
  phenotype_term:
    preferred_term: Pulmonary cyst
    term:
      id: HP:0032445
      label: Pulmonary cyst
  evidence:
  - reference: PMID:42012654
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "benign congenital lung malformations such as congenital pulmonary airway malformation (CPAM, formerly congenital cystic adenomatoid malformation or CCAM)"
    explanation: CPAM is classified among cystic congenital lung malformations.
histopathology:
- name: Mucinous Cell Clusters in Type 1 CPAM
  description: >
    Foci of mucinous cell clusters within otherwise non-mucinous CPAM
    epithelium are a recognized histologic finding, particularly in type 1
    lesions, and harbor KRAS mutations identical to those in adjacent
    non-mucinous areas.
  evidence:
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Possible findings are foci of mucinous cell clusters (MCCs), harboring KRAS mutations."
    explanation: Mucinous cell clusters with KRAS mutations are a recognized histologic finding in CPAM.
- name: Mixed Type 1 and Type 2 Patterns
  description: >
    A substantial subset of CPAM lesions show mixed type 1 and type 2
    histologic patterns within the same specimen, supporting a continuum
    model of developmental disturbance rather than discrete subtypes.
  evidence:
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A mixed pattern of types 1 and 2 was observed in 22%."
    explanation: Mixed type 1/2 histology is present in roughly one-fifth of CPAM specimens in a 46-case series.
- name: CK7/TTF-1 Positive Epithelium
  description: >
    The epithelial lining of CPAM is consistently positive for CK7 and
    TTF-1, with variable expression of Napsin A, surfactant protein A,
    p40, CK5/6, and CK20 by subtype.
  evidence:
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The epithelial lining was strongly positive for CK7 and TTF-1 in all samples."
    explanation: Uniform CK7/TTF-1 positivity defines the lung-epithelial origin of CPAM lining.
treatments:
- name: Anatomic Lobectomy
  description: >
    Anatomic lobectomy is the most common definitive surgical treatment
    for CPAM in U.S. pediatric practice, used in approximately 88% of
    resections, and is increasingly performed via video-assisted
    thoracoscopic surgery (VATS), which is associated with shorter
    hospital stay and lower 30-day complication rates than open lobectomy.
  treatment_term:
    preferred_term: lobectomy
    term:
      id: NCIT:C15272
      label: Lobectomy
  evidence:
  - reference: PMID:41945161
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Lobectomy (n = 1,865; 88%) was performed far more often than sublobar resection (n = 245; 12%)"
    explanation: Lobectomy was the predominant resection approach in a 10-year U.S. NSQIP-Pediatric review.
  - reference: PMID:41945161
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "VATS was utilized more often than open surgery for both lobectomy (57.8%) and sublobar resections (54.7%) and was associated with lower 30-day complication rates (OR 0.58, p < 0.01) and total hospital length of stay (-1.48 days, p < 0.0001) after lobectomy."
    explanation: VATS is the predominant approach for pediatric CPAM lobectomy and is associated with reduced complications and shorter hospital stays.
- name: Sublobar Resection (Segmentectomy or Wedge)
  description: >
    Sublobar resection (anatomic segmentectomy or wedge resection) is a
    lung-sparing alternative to lobectomy for selected CPAM lesions.
    Anatomic segmentectomy is associated with fewer 30-day complications
    than lobectomy in large registry data.
  treatment_term:
    preferred_term: pulmonary segmentectomy
    term:
      id: NCIT:C91061
      label: Segmentectomy
  evidence:
  - reference: PMID:41945161
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Segmentectomy was associated with significantly fewer 30-day complications compared to lobectomy (OR 0.08, p < 0.0001)"
    explanation: Anatomic segmentectomy is associated with fewer 30-day complications than lobectomy in pediatric CPAM resection.
- name: Expectant (Conservative) Management
  description: >
    For asymptomatic, antenatally-diagnosed CPAMs, contemporary evidence
    supports observational management with serial imaging in selected
    patients, with low rates of serious adverse outcomes and no reported
    malignancy in medium-term follow-up.
  treatment_term:
    preferred_term: watchful waiting
    term:
      id: MAXO:0000950
      label: supportive care
  evidence:
  - reference: PMID:41643769
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In asymptomatic patients with mainly antenatally diagnosed lesions, conservative management of CPAM lesions was associated with a complication rate and no reported cases of mortality or malignancy."
    explanation: A 298-patient systematic review supports the safety of conservative management of asymptomatic CPAM with medium-term follow-up.
  - reference: PMID:41643769
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A total of 58 patients (20%) eventually underwent surgical resection due to complications, lesion progression, or parental preference."
    explanation: Approximately 20% of conservatively managed asymptomatic CPAM patients ultimately undergo resection.
- name: Fetal Thoracoamniotic Shunting
  description: >
    Thoracoamniotic shunting (TAS) is the standard fetal intervention for
    severe macrocystic CPAM, particularly when complicated by fetal
    hydrops. TAS achieves resolution of hydrops and lesion regression in
    the great majority of treated fetuses.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  evidence:
  - reference: PMID:41557046
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Resolution of hydrops and regression of the lesion occurred in 96% (24/25)."
    explanation: TAS achieved resolution of hydrops and lesion regression in 96% of treated severe macrocystic CPAM fetuses.
- name: Fetal Radiofrequency Ablation
  description: >
    For microcystic CPAM complicated by fetal hydrops and refractory to
    maternal steroid therapy, ultrasound-guided radiofrequency ablation
    (RFA) is described as a salvage intrauterine intervention, though it
    carries a meaningful risk of intrauterine fetal demise.
  treatment_term:
    preferred_term: radiofrequency ablation
    term:
      id: NCIT:C15666
      label: Radiofrequency Ablation
  evidence:
  - reference: PMID:41545807
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For microcystic CPAM complicated with fetal hydrops and refractory to maternal conservative steroid administration, ultrasound-guided RFA serves as an effective salvage option for intrauterine treatment."
    explanation: Ultrasound-guided RFA is described as a salvage option for microcystic CPAM complicated by fetal hydrops refractory to steroids.
- name: Maternal Antenatal Corticosteroids
  description: >
    Maternal corticosteroid administration is used for large microcystic
    CPAM lesions to reduce mass effect and prevent or reverse fetal
    hydrops, with intrauterine intervention reserved for refractory cases.
  treatment_term:
    preferred_term: corticosteroid agent therapy
    term:
      id: MAXO:0000640
      label: corticosteroid agent therapy
  evidence:
  - reference: PMID:41545807
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All cases received two courses of maternal steroid before the RFA procedure."
    explanation: Maternal steroid courses are standard first-line therapy for severe microcystic CPAM in this referral series.
genetic:
- name: DICER1 germline variants (former CPAM type 4 / cystic PPB overlap)
  gene_term:
    preferred_term: DICER1
    term:
      id: hgnc:17098
      label: DICER1
  variant_origin: GERMLINE
  association: Pathogenic Variants
  inheritance:
  - name: Autosomal dominant
  notes: >
    Germline DICER1 pathogenic variants define DICER1 tumor predisposition
    syndrome and underlie cystic (type I) pleuropulmonary blastoma, which
    overlaps clinically and radiographically with former CPAM type 4.
    Distinguishing PPB from CPAM is critical for oncologic management and
    DICER1 surveillance.
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "germline variants in congenital acinar dysplasia, formerly CPAM type 0, and pleuropulmonary blastoma (PPB), type I, formerly CPAM type 4"
    explanation: The Stocker reconsideration links germline variants to former CPAM types 0 and 4 (the PPB type I overlap).
  - reference: PMID:42012654
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "histopathology and genetics-especially DICER1 mutation-in the diagnosis and therapeutic decision-making of pleuropulmonary blastoma."
    explanation: DICER1 mutation analysis is central to distinguishing PPB from benign cystic congenital lung malformations including CPAM.
- name: Somatic KRAS mosaic variants (CPAM types 1 and possibly 3)
  gene_term:
    preferred_term: KRAS
    term:
      id: hgnc:6407
      label: KRAS
  variant_origin: SOMATIC
  association: Pathogenic Variants
  notes: >
    Somatic activating KRAS mutations (commonly G12D, G12V) are detected
    in CPAM types 1 and possibly 3, localized to mucinous cell clusters
    and adjacent non-mucinous epithelium, and are interpreted as a clonal
    precursor alteration for mucinous adenocarcinoma progression.
  evidence:
  - reference: PMID:37334833
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "mutational events either at the somatic level in KRAS (CPAM types 1 and possibly 3)"
    explanation: The Stocker reconsideration assigns somatic KRAS alterations to CPAM types 1 and possibly 3.
  - reference: PMID:40473982
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mutations were found in 24% (9 × KRAS; 2 × FGFR2). Besides classical KRAS mutations (G12D, G12V), two cases showed a double-mutation pattern (G12D/G12V; G12D/TP53)."
    explanation: A 46-lesion molecular series identifies somatic KRAS G12D/G12V as the predominant alteration.
datasets:
📚

References & Deep Research

Deep Research

1
Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 38 citations 2026-05-13T14:52:41.140757

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Congenital Pulmonary Airway Malformation
  • MONDO ID: (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on Congenital Pulmonary Airway Malformation covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Comprehensive Research Report: Congenital Pulmonary Airway Malformation (CPAM)

1. Disease Information

Definition/overview. Congenital pulmonary airway malformation (CPAM) is a congenital lung malformation characterized by abnormal airway development producing cystic and/or solid pulmonary lesions, most often limited to a single lobe, and commonly detected on prenatal ultrasonography. CPAM is historically referred to as congenital cystic adenomatoid malformation (CCAM); however, CPAM is preferred because “only three of five types are cystic” and only one type is “adenomatoid.” (cancemi2024congenitallungmalformations pages 5-6, pederiva2023congenitallungmalformations pages 1-6)

Synonyms/alternative names. - Congenital cystic adenomatoid malformation (CCAM) (pederiva2023congenitallungmalformations pages 1-6, bertolino2024congenitalpulmonaryairway pages 1-2) - Congenital lung malformation / congenital thoracic malformation (broader umbrella terms used in reviews) (eber2024lungmalformationspredicting pages 1-2, pederiva2023congenitallungmalformations pages 1-6)

Key identifiers. In the retrieved evidence, CPAM is consistently referred to as a congenital lung malformation entity but explicit OMIM/Orphanet/MONDO/MeSH codes were not available in the accessible full texts; thus identifiers cannot be reliably populated from this tool-based retrieval.

Evidence provenance. The information summarized here is derived primarily from aggregated disease-level resources (reviews and cohort studies) and supplemented by case series/case reports and ClinicalTrials.gov registry entries (pederiva2023congenitallungmalformations pages 1-6, bertolino2024congenitalpulmonaryairway pages 1-2, kunisaki2021narrativereviewof pages 1-2, NCT05701514 chunk 1).

2. Etiology

Developmental etiology. CPAM is considered a developmental disorder of lung branching/airway morphogenesis, rather than an infectious disease, with most cases occurring sporadically and without clear maternal risk factors. A narrative review notes these lesions are “generally sporadic” and not associated with karyotype anomalies (kunisaki2021narrativereviewof pages 1-2).

Somatic mosaic driver mutations (current understanding). A major 2023 synthesis and a high-impact 2024 genetics letter support a model in which many CPAMs—especially types 1 and 3—are driven by somatic mosaic oncogenic RAS–MAPK pathway variants, most commonly KRAS (pederiva2023congenitallungmalformations pages 13-16, windrich2024rasmapkpathwaymutations pages 1-2).

  • In a 2024 American Journal of Respiratory and Critical Care Medicine report, somatic mosaic KRAS mutations were detected in 17/29 (58.6%) CPAM type 1 lesions; the most frequent was KRAS c.35G>A (p.G12D) (12/17 mutated cases), with additional variants including p.G12R, p.A11_G12dup, p.G12V, p.G12C (URL: https://doi.org/10.1164/rccm.202311-2163le; published May 2024) (windrich2024rasmapkpathwaymutations pages 1-2, windrich2024rasmapkpathwaymutations pages 2-3).
  • The same report identified a somatic BRAF c.1799T>A (p.V600E) mutation in a CPAM type 3 lesion, with mutant protein expression confirmed by BRAF V600E immunohistochemistry (windrich2024rasmapkpathwaymutations pages 2-3, windrich2024rasmapkpathwaymutations pages 3-3).

Epigenetic and -omics signals. Whole-genome methylation differences and transcriptomic pathway enrichment (Ras complex, PI3K–AKT–mTOR, mTOR signaling, Myc targets) have been reported in CPAM and may relate to dysregulated proliferation/survival programs during development (pederiva2023congenitallungmalformations pages 6-9, pederiva2023congenitallungmalformations pages 9-13).

Risk and protective factors. The accessible sources emphasize developmental and somatic mosaic mechanisms; robust, reproducible environmental risk factors or protective factors were not identified in the retrieved evidence.

Gene–environment interactions. No specific gene–environment interactions were identified in the retrieved evidence.

3. Phenotypes

Typical clinical spectrum. CPAM ranges from asymptomatic prenatal/postnatal findings to neonatal respiratory failure. - Postnatal presentation “ranges from asymptomatic infants to respiratory failure” in congenital lung malformations including CPAM (pederiva2023congenitallungmalformations pages 1-6). - Up to ~70% may be asymptomatic in some clinical descriptions (ottomeyer2023earlyresectionof pages 6-7).

Prenatal phenotypes and complications. Prenatal ultrasound may show a cystic/solid lung mass with mediastinal shift; severe cases develop polyhydramnios or hydrops fetalis, which is the strongest adverse prognostic factor (bertolino2024congenitalpulmonaryairway pages 1-2, ottomeyer2023earlyresectionof pages 6-7).

Postnatal symptoms/signs and complications. Recurrent pneumonia, pneumothorax, and rarely malignancy are common cited reasons for elective resection (kunisaki2021narrativereviewof pages 1-2). In a 2010–2020 institutional series of congenital pulmonary malformations (Peru), postoperative complications after surgery included pneumonia (12.9%), pneumothorax (7.1%), atelectasis (5.7%), and others (nunezpaucar2023congenitalpulmonarymalformations pages 4-5).

Suggested HPO terms (examples; not exhaustive). - Abnormality of the lung (HP:0100753) - Congenital pulmonary airway malformation (disease-specific HPO term may not exist; often represented via structural terms) - Respiratory distress in the newborn (HP:0002643) - Pulmonary hypoplasia (HP:0002089) (reported as a complication in clinical series) (pederiva2023congenitallungmalformations pages 20-24) - Pneumothorax (HP:0002107) (nunezpaucar2023congenitalpulmonarymalformations pages 4-5) - Recurrent respiratory infections / pneumonia (HP:0002205 / HP:0002090) (nunezpaucar2023congenitalpulmonarymalformations pages 4-5, kunisaki2021narrativereviewof pages 1-2) - Fetal hydrops (HP:0001789) (pederiva2023congenitallungmalformations pages 20-24, ottomeyer2023earlyresectionof pages 6-7) - Mediastinal shift (HP:0030749) - Polyhydramnios (HP:0001561)

Phenotype frequencies (available in retrieved evidence). - Prenatal detection in a multidisciplinary follow-up cohort: prenatal ultrasound diagnosis in 88.8% of CPAM cases (n=9) (mussi2024respiratoryfollowupin pages 2-3). - In the Peru series, CPAM constituted 55.7% (39/70) of congenital pulmonary malformations seen (nunezpaucar2023congenitalpulmonarymalformations pages 4-5).

Quality-of-life impact. Direct standardized QoL metrics are not reported in the accessible publications; however, the ongoing RCT includes child QoL and parental anxiety as key endpoints (NCT05701514 chunk 2).

4. Genetic/Molecular Information

Causal genes. CPAM is generally described as not inheritable, and the strongest current genetic evidence implicates somatic mosaic mutations rather than germline Mendelian inheritance for many cases (pederiva2023congenitallungmalformations pages 6-9, pederiva2023congenitallungmalformations pages 13-16).

Pathogenic variants and molecular subtypes (best-supported). - KRAS (somatic mosaic; most frequently codon 12 variants in type 1/3) (windrich2024rasmapkpathwaymutations pages 1-2, windrich2024rasmapkpathwaymutations pages 2-3, pederiva2023congenitallungmalformations pages 9-13). - BRAF p.V600E (somatic mosaic; reported in type 3 in one cohort) (windrich2024rasmapkpathwaymutations pages 2-3, windrich2024rasmapkpathwaymutations pages 3-3). - DICER1 (germline and/or somatic in the pleuropulmonary blastoma spectrum; relevant to CPAM type 4 vs PPB differential) (pederiva2023congenitallungmalformations pages 13-16, windrich2024rasmapkpathwaymutations pages 2-3, cancemi2024congenitallungmalformations pages 4-5).

Putative premalignant histology-molecular correlate. Mucinous cell clusters (MCCs) are described as common in CPAM type 1 and linked to KRAS mutations; a 2024 genetics study notes mucinous clusters “may transform into mucinous adenocarcinoma,” motivating malignancy-risk discussions in management (windrich2024rasmapkpathwaymutations pages 1-2, pederiva2023congenitallungmalformations pages 9-13).

Epigenetics. Differential methylation in developmental and proliferation genes across congenital lung malformations, including CPAM, has been reported (pederiva2023congenitallungmalformations pages 9-13, pederiva2023congenitallungmalformations pages 6-9).

Modifier genes / protective variants. Not identified in the retrieved evidence.

5. Mechanism / Pathophysiology

Mechanistic model (causal chain). 1. Early developmental perturbation in epithelial–mesenchymal signaling/branching morphogenesis produces abnormal airway structures (review synthesis) (pederiva2023congenitallungmalformations pages 1-6). 2. In a substantial subset, somatic mosaic oncogenic activation of RAS–MAPK (KRAS; occasionally BRAF) in airway epithelium drives localized dysplastic proliferation and aberrant differentiation, producing macrocystic/microcystic/solid lesions (pederiva2023congenitallungmalformations pages 13-16, windrich2024rasmapkpathwaymutations pages 1-2, windrich2024rasmapkpathwaymutations pages 3-3). 3. Lesion mass effect can cause mediastinal shift, impaired venous return, and fetal heart failure physiology leading to hydrops in high-risk cases; size-based indices (CVR) track this risk (pederiva2023congenitallungmalformations pages 20-24). 4. Postnatally, retained abnormal tissue predisposes to air trapping, recurrent infections, pneumothorax, and in rare circumstances neoplastic evolution (mucinous adenocarcinoma/PPB spectrum) (pederiva2023congenitallungmalformations pages 1-6, cancemi2024congenitallungmalformations pages 4-5).

Upstream vs downstream. Somatic KRAS/BRAF activation is an upstream lesion-driver in many cases; downstream consequences include altered proliferation/apoptosis (reported “double proliferation index” and lower apoptosis susceptibility) and pathway-level upregulation of Ras/PI3K–mTOR/Myc programs (pederiva2023congenitallungmalformations pages 6-9).

Relevant GO biological process terms (suggestions). - Branching morphogenesis of an epithelial tube (GO:0061138) - Lung development (GO:0030324) - Regulation of epithelial cell proliferation (GO:0050678) - Ras protein signal transduction (GO:0007265) - MAPK cascade (GO:0000165) - PI3K signaling (GO:0014065) / mTOR signaling

Relevant CL (cell type) terms (suggestions). - Airway epithelial cell (CL:0000066) - Alveolar type II cell (CL:0002063) (marker associations discussed in CPAM molecular phenotyping literature; see also proteomic study context) () - Smooth muscle cell (CL:0000192)

6. Inheritance and Population

Inheritance pattern. CPAM is typically sporadic and described as “not inheritable” in a 2023 authoritative review (pederiva2023congenitallungmalformations pages 6-9).

Incidence / prevalence. Estimates vary by study design and ascertainment. - A 2024 review states CPAM affects ~1 in 2,500 live births and notes that lesions often enlarge in second trimester and may regress (URL: https://doi.org/10.3390/life14080990; published Aug 2024) (bertolino2024congenitalpulmonaryairway pages 1-2). - A 2023 Nature Reviews Disease Primers synthesis reports overall congenital lung malformation incidence of ~4 per 10,000 live births and also notes registry-derived estimates around ~1 per 2,500 live births for CLMs (URL: https://doi.org/10.1038/s41572-023-00470-1; published Nov 2023) (pederiva2023congenitallungmalformations pages 1-6, pederiva2023congenitallungmalformations pages 6-9).

Sex ratio. A male predominance is mentioned in a 2024 case report review, but robust population-level sex ratio estimates were not extracted from high-quality cohort data in the retrieved evidence (goli2024earlydetectionand pages 1-2).

7. Diagnostics

Prenatal imaging. Serial fetal ultrasound is the primary modality, typically at 18–22 weeks, characterizing lesion size, cystic vs solid features, mediastinal shift, pleural effusion, and hydrops (pederiva2023congenitallungmalformations pages 16-20, cancemi2024congenitallungmalformations pages 4-5).

CVR (CPAM/CLM volume ratio): definition and thresholds. - CVR formula: lesion length × width × height × 0.52 divided by head circumference (cancemi2024congenitallungmalformations pages 5-6, kane2020theutilityof pages 1-2). - Thresholds reported in authoritative synthesis: - CVR > 1.6 associated with ~80% risk of fetal hydrops (pederiva2023congenitallungmalformations pages 20-24). - CVR > 0.84 predicts respiratory morbidities/respiratory distress at birth and is linked to likelihood of surgery (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 5-6). - Maximum CVR < 0.40 associated with neonatal respiratory distress probability <10% (pederiva2023congenitallungmalformations pages 20-24). - A systematic review emphasizes that lower thresholds (0.5–1.0; even ~0.4) may better predict broader neonatal outcomes depending on population and endpoints (kane2020theutilityof pages 1-2).

Role of fetal MRI. Fetal MRI can aid in lesion characterization and sometimes vascular assessment; some reviews note limited incremental value over expert ultrasound, whereas others recommend selective MRI for unclear or large lesions (bertolino2024congenitalpulmonaryairway pages 1-2, pederiva2023congenitallungmalformations pages 20-24).

Postnatal imaging. - Chest radiograph is initial but limited; one synthesis states it “misses ~50% of CLMs” (pederiva2023congenitallungmalformations pages 20-24). - Chest CT angiography (CTA) is described as the gold standard for confirmation and surgical planning, often around ~2 months or within the first 6 months depending on symptoms (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 5-6, ottomeyer2023earlyresectionof pages 6-7).

Differential diagnosis. Key entities include pulmonary sequestration (including hybrid lesions), congenital lobar overinflation (CLO), bronchogenic cyst, congenital diaphragmatic hernia, and pleuropulmonary blastoma (PPB) (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 4-5, gonzalez2024congenitalpulmonaryairway pages 4-5).

8. Outcome/Prognosis

Natural history and prognosis. Many lesions plateau and regress late in gestation; overall prognosis is generally excellent in the absence of hydrops and severe pulmonary hypoplasia, but outcomes vary with lesion size and physiology (bertolino2024congenitalpulmonaryairway pages 1-2, kunisaki2021narrativereviewof pages 1-2).

Quantitative prenatal course. A 2024 review states many CPAMs grow in the second trimester, plateau, and in “about 50%” regress by the third trimester (bertolino2024congenitalpulmonaryairway pages 1-2). A separate review of CPAM in an extreme preterm infant reports ranges of in-utero regression (8–42%) and complete resolution (11–49%) across series (ottomeyer2023earlyresectionof pages 6-7).

Complications and malignancy risk. Malignancy risk is discussed as a rationale for resection but remains uncertain in true incidence; the 2023 synthesis cites historical estimates and emphasizes knowledge gaps (pederiva2023congenitallungmalformations pages 6-9, pederiva2023congenitallungmalformations pages 1-6). Molecular data linking KRAS-mutant mucinous clusters to mucinous adenocarcinoma provide mechanistic plausibility for rare malignant evolution (windrich2024rasmapkpathwaymutations pages 1-2, pederiva2023congenitallungmalformations pages 9-13).

9. Treatment

Prenatal interventions (high-risk lesions). - Maternal corticosteroids are described as standard-of-care for larger lesions at risk of nonimmune hydrops (kunisaki2021narrativereviewof pages 1-2). - Thoracoamniotic shunt is used for large cysts with mass effect; open fetal surgery is rare due to morbidity; EXIT may be used for severe airway compromise (bertolino2024congenitalpulmonaryairway pages 2-5, kunisaki2021narrativereviewof pages 1-2).

Postnatal management. - Symptomatic infants with respiratory distress may need urgent surgical resection (kunisaki2021narrativereviewof pages 1-2, ottomeyer2023earlyresectionof pages 6-7). - Elective resection for asymptomatic lesions is debated; many centers recommend resection within the first year to reduce complications and enable compensatory lung growth (bertolino2024congenitalpulmonaryairway pages 1-2, pederiva2023congenitallungmalformations pages 1-6, ottomeyer2023earlyresectionof pages 6-7). - Surgical approaches include open lobectomy and thoracoscopic (VATS) resections; minimally invasive approaches are common when feasible (kunisaki2021narrativereviewof pages 1-2, mussi2024respiratoryfollowupin pages 2-3).

Real-world outcomes data (examples). - Peru single-center congenital pulmonary malformation cohort (2010–2020; n=70; CPAM 39/70): lobectomy 87.1%, postoperative pneumonia 12.9%, pneumothorax 7.1%, with no in-hospital deaths (URL: https://doi.org/10.24875/bmhim.23000055; published Sep 2023) (nunezpaucar2023congenitalpulmonarymalformations pages 4-5). - Multidisciplinary follow-up cohort (Italy; CPAM n=9): surgery in 7/9 (77.7%), with VATS in 4, and some longer-term wheezing requiring inhaled corticosteroids (mussi2024respiratoryfollowupin pages 2-3).

MAXO term suggestions (examples). - Surgical excision of lung lesion / lobectomy (MAXO term: surgical resection) - Thoracoscopic surgery (MAXO: minimally invasive surgery) - Prenatal corticosteroid therapy (MAXO: glucocorticoid therapy) - Fetal thoracoamniotic shunt placement (MAXO: fetal shunt placement) - EXIT procedure (MAXO: ex utero intrapartum treatment)

10. Prevention

Primary prevention. No validated primary prevention exists for CPAM because it is a congenital developmental malformation (pederiva2023congenitallungmalformations pages 1-6).

Secondary prevention (risk mitigation). Prevention in practice focuses on prenatal detection (screening ultrasound), risk stratification (CVR), and referral to tertiary fetal medicine/pediatric surgery centers for high-risk lesions (pederiva2023congenitallungmalformations pages 20-24, kunisaki2021narrativereviewof pages 1-2).

Tertiary prevention. Postnatal prevention targets avoiding recurrent infection, pneumothorax, and rare malignant transformation via appropriate imaging follow-up and (in selected patients) resection (pederiva2023congenitallungmalformations pages 1-6, kunisaki2021narrativereviewof pages 1-2).

11. Other Species / Natural Disease

No naturally occurring veterinary analogue or species-specific CPAM entity was identified in the retrieved evidence.

12. Model Organisms

The retrieved evidence emphasizes human lesion genomics and -omics rather than established animal models. However, mechanistic framing (mosaic RASopathies; epithelial driver mutations) implies relevant experimental systems could include mosaic KRAS/BRAF activation in lung epithelium during development; specific validated model organisms were not identified in the accessible evidence.

13. Anatomical Structures Affected

Organ/system. Lung (respiratory system), typically a single lobe; prenatal mass effect can involve mediastinum and fetal cardiovascular physiology (pederiva2023congenitallungmalformations pages 6-9, pederiva2023congenitallungmalformations pages 20-24).

UBERON term suggestions. - Lung (UBERON:0002048) - Lung lobe (UBERON:0002173) - Bronchiole / airway epithelium (UBERON airway structures) - Mediastinum (UBERON:0003729)

14. Temporal Development

Onset. Congenital; usually detected prenatally at ~18–22 weeks (pederiva2023congenitallungmalformations pages 16-20).

Gestational course. Lesions often grow between 20–26 weeks and plateau by ~29 weeks; a substantial fraction regress in late gestation (pederiva2023congenitallungmalformations pages 16-20, bertolino2024congenitalpulmonaryairway pages 1-2).

15. Recent Developments and Latest Research (2023–2024 emphasis)

High-authority synthesis (2023). Nature Reviews Disease Primers published a comprehensive 2023 review of congenital lung malformations, summarizing epidemiology, imaging workflows (CTA as gold standard), CVR thresholds for hydrops and neonatal distress, and highlighting the unresolved debate about resection vs conservative management for asymptomatic lesions (URL: https://doi.org/10.1038/s41572-023-00470-1; published Nov 2023) (pederiva2023congenitallungmalformations pages 1-6, pederiva2023congenitallungmalformations pages 20-24).

Molecular genetics leap (2024). A 2024 AJRCCM letter expanded evidence that CPAM types 1 and 3 frequently harbor somatic mosaic oncogenic RAS–MAPK variants, quantifying mutation frequencies and cataloging KRAS and BRAF variants; it also frames CPAM as “possible mosaic RASopathies,” which is mechanistically consequential and may influence long-term malignancy-risk evaluation (URL: https://doi.org/10.1164/rccm.202311-2163le; published May 2024) (windrich2024rasmapkpathwaymutations pages 1-2, windrich2024rasmapkpathwaymutations pages 2-3, windrich2024rasmapkpathwaymutations pages 3-3).

Imaging-focused implementation guidance (2024). A 2024 pictorial review provides practical diagnostic imaging guidance (prenatal US; CVR formula and ≥0.84 threshold; CT within first 6 months; CTA for vascular mapping; MRI alternatives) that supports real-world radiology workflow standardization (URL: https://doi.org/10.3390/children11060638; published May 2024) (cancemi2024congenitallungmalformations pages 5-6, cancemi2024congenitallungmalformations pages 4-5).

Expert opinions and analysis (from authoritative sources)

  • Surgery vs observation remains the key unresolved question for asymptomatic infants: clinicians “agree to surgically treat symptomatic patients,” but “there is an ongoing debate worldwide whether asymptomatic patients should be managed surgically or conservatively” (pederiva2023congenitallungmalformations pages 6-9). This uncertainty is sufficiently impactful that a multicenter RCT has been launched (CONNECT) (NCT05701514 chunk 1).
  • Size-based fetal risk prediction is central: multiple sources emphasize that mass size/CVR is more prognostic than histologic type for perinatal outcomes (pederiva2023congenitallungmalformations pages 20-24, eber2024lungmalformationspredicting pages 1-2).
  • Molecular stratification is emerging: KRAS/BRAF mosaicism suggests CPAM is not purely “malformative” but can be viewed as congenital tissue dysplasia driven by oncogenic mutations, potentially reshaping surveillance strategies and malignancy-risk counseling (windrich2024rasmapkpathwaymutations pages 3-3, pederiva2023congenitallungmalformations pages 13-16).

Current applications and real-world implementations

  • Prenatal monitoring programs: serial ultrasound with CVR tracking and selective fetal MRI for high-risk/uncertain lesions are widely implemented (pederiva2023congenitallungmalformations pages 20-24).
  • Postnatal confirmation and surgical planning: CT angiography (often at ~2 months or within 6 months) is used for definitive characterization and vascular mapping prior to resection (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 5-6).
  • Multidisciplinary care pathways: cohort follow-up models integrate pulmonology, surgery, neonatology, and radiology to manage short- and long-term respiratory complications (mussi2024respiratoryfollowupin pages 2-3).

Relevant statistics and quantitative data highlights

  • Incidence: frequently cited ~1/2,500 live births (bertolino2024congenitalpulmonaryairway pages 1-2, kunisaki2021narrativereviewof pages 1-2).
  • Prenatal natural history: ~50% regression by third trimester in one 2024 review (bertolino2024congenitalpulmonaryairway pages 1-2).
  • CVR risk thresholds: >1.6 → ~80% hydrops risk; >0.84 → predicts respiratory morbidity; <0.40 → NRD probability <10% (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 5-6).
  • Genetics: somatic KRAS mutations in 17/29 (58.6%) type 1 lesions; common KRAS p.G12D (windrich2024rasmapkpathwaymutations pages 1-2).

Ongoing clinical trials/registries (real-world evidence generation)

  • CONNECT trial (NCT05701514): randomized trial of elective resection (6–9 months) vs watchful waiting in asymptomatic, CT-confirmed CPAM; primary endpoint exercise tolerance at 5 years (BRUCE treadmill) (registered 2023; recruiting) (NCT05701514 chunk 1, NCT05701514 chunk 2).
  • Swiss Congenital Lung Anomalies registry/biobank (NCT03044769): prospective 10-year registry with imaging, lung function, and tissue biomarker endpoints (registered 2016) (NCT03044769 chunk 1).
  • Molecular profiling study (NCT01732185): completed basic-science interventional study collecting blood and lesion/adjacent tissue for transcriptomics/proteomics and CGH-array somatic abnormalities (2012–2015; n=45) (NCT01732185 chunk 1).
  • Surgical outcomes review (NCT04449614): completed retrospective cohort of thoracoscopic CPAM resections (2008–2017; n=72) (NCT04449614 chunk 1).

Visual evidence from retrieved documents

The following cropped figure-legend excerpts (manuscript draft text) summarize the presence of key classification/management figures (Stocker classification and CVR-based algorithms) in the 2023 authoritative review; the actual figure panels were not included in the accessible text, but the legends contain the quantitative thresholds and algorithm descriptions (pederiva2023congenitallungmalformations media 94ace63e, pederiva2023congenitallungmalformations media 92254196, pederiva2023congenitallungmalformations media 769ac597).

High-yield structured summary (artifact)

Domain Key facts (include numeric values/thresholds) Best recent/authoritative source (with year, journal) Evidence note (include one short direct quote snippet when available)
Definition/synonyms CPAM is a congenital lung malformation; older term CCAM remains common. CPAM is preferred because not all types are cystic/adenomatoid. Five histologic subtypes are recognized in modern Stocker classification. Pederiva et al., 2023, Nature Reviews Disease Primers; Cancemi et al., 2024, Children “congenital cystic adenomatoid malformation (CCAM)” is used as a synonym for CPAM; CPAM is preferred because “only three of five types are cystic” (pederiva2023congenitallungmalformations pages 1-6, cancemi2024congenitallungmalformations pages 5-6)
Incidence Population estimates vary: CPAM/CLM incidence is often cited around 1 in 2,500 live births; broader CLM incidence reported as 4 per 10,000 live births. Bertolino et al., 2024, Life; Pederiva et al., 2023, Nature Reviews Disease Primers Bertolino review states CPAMs affect “1 in 2500 live births” (bertolino2024congenitalpulmonaryairway pages 1-2, pederiva2023congenitallungmalformations pages 1-6)
Prenatal natural history Typically detected at 18–22 weeks; many lesions enlarge during the 2nd trimester, peak around 20–26 weeks, then plateau by ~29 weeks; ~50% may regress and become barely detectable in the 3rd trimester. Reported in-utero regression ranges 8–42%; complete prenatal resolution 11–49% in some series. Pederiva et al., 2023, Nature Reviews Disease Primers; Bertolino et al., 2024, Life; Ottomeyer et al., 2023, BMC Pediatrics “increase their size in the second trimester, reach a plateau, and, in about 50% of cases, regress” (bertolino2024congenitalpulmonaryairway pages 1-2, pederiva2023congenitallungmalformations pages 16-20, ottomeyer2023earlyresectionof pages 6-7)
Stocker classification overview Modern Stocker types 0–4: type 1 is most common (~50–70% or 60–65%); type 2 ~15–30% or 10–40%; type 3 ~5–10%; type 4 ~10–15%; type 0 ~2%. Type 1 often has large cysts >2 cm; type 2 multiple small cysts; type 3 solid/microcystic; type 4 peripheral/acinar large cystic lesions. Pederiva et al., 2023, Nature Reviews Disease Primers; Cancemi et al., 2024, Children Stocker classification “classified into five histological subtypes” and type frequencies are summarized in recent imaging review (pederiva2023congenitallungmalformations pages 1-6, cancemi2024congenitallungmalformations pages 5-6)
CVR thresholds (0.40, 0.84, 1.6) CVR = lesion length × width × height × 0.52 / head circumference. CVR <0.40: low risk, neonatal respiratory distress <10%; CVR ≥0.84: predicts respiratory distress at birth / respiratory morbidity and likely need for surgery; CVR >1.6: associated with ~80% risk of fetal hydrops. Lower neonatal-risk thresholds of 0.5–1.0 have also been proposed. Pederiva et al., 2023, Nature Reviews Disease Primers; Cancemi et al., 2024, Children; Kane et al., 2020, Fetal Diagnosis and Therapy “CVR > 1.6 associates with ~80% risk of fetal hydrops”; “A CVR value of ≥0.84 is a reliable predictor of respiratory distress at birth” (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 5-6, kane2020theutilityof pages 1-2)
Management controversy Symptomatic CPAM is generally resected; the main controversy is asymptomatic disease. Many centers recommend elective resection in the first year, but some surgeons favor observation because the true risk of infection/malignancy is uncertain. Pederiva et al., 2023, Nature Reviews Disease Primers; Bertolino et al., 2024, Life; Kunisaki, 2021, Translational Pediatrics “there is an ongoing debate worldwide whether asymptomatic patients should be managed surgically or conservatively” (pederiva2023congenitallungmalformations pages 6-9, pederiva2023congenitallungmalformations pages 1-6, bertolino2024congenitalpulmonaryairway pages 1-2)
Molecular genetics (KRAS, BRAF, DICER1/PPB) Strongest current evidence supports somatic mosaic RAS-MAPK alterations in CPAM, especially types 1 and 3. KRAS mutations found in 17/29 (58.6%) type 1 cases in one 2024 series; common variants include p.G12D, p.G12V, p.G12C, p.G12R, p.A11_G12dup. Somatic BRAF p.V600E has also been reported. Type 4/PPB overlap is linked to DICER1; PPB type 1 cases in the 2024 series had DICER1 variants rather than RAS-MAPK mutations. Windrich et al., 2024, American Journal of Respiratory and Critical Care Medicine; Pederiva et al., 2023, Nature Reviews Disease Primers “CPAM Type 1 results from somatic KRAS mutations”; somatic BRAF p.V600E was also detected; DICER1 is linked to PPB/type 4 biology (windrich2024rasmapkpathwaymutations pages 1-2, windrich2024rasmapkpathwaymutations pages 2-3, pederiva2023congenitallungmalformations pages 13-16, windrich2024rasmapkpathwaymutations pages 3-3)
Diagnostic imaging Prenatal ultrasound is the primary screening and surveillance tool; detects lesion size, cystic/solid nature, mediastinal shift, hydrops, and systemic feeding vessel assessment by Doppler. Fetal MRI is adjunctive for unclear/large lesions and vascular anatomy. Postnatally, chest radiograph is first-line but insensitive (~50% may be missed); chest CT angiography around ~2 months or within first 6 months is the diagnostic gold standard for confirmation and surgical planning. Pederiva et al., 2023, Nature Reviews Disease Primers; Cancemi et al., 2024, Children “chest radiograph is first-line but misses ~50% of CLMs”; CTA is the “gold standard” for confirmation and planning (pederiva2023congenitallungmalformations pages 20-24, cancemi2024congenitallungmalformations pages 5-6, cancemi2024congenitallungmalformations pages 4-5)
Treatment options Prenatal: maternal corticosteroids for larger/high-risk microcystic lesions; thoracoamniotic shunt for large macrocystic lesions with mass effect; open fetal surgery rarely used; EXIT considered for severe airway/mediastinal compromise. Postnatal: urgent surgery for respiratory distress; elective resection often in first year (median age 5 months in one review); thoracoscopic surgery is widely used when feasible. In one Peruvian CPM series, lobectomy was 87.1% of operations; postoperative pneumonia 12.9%, pneumothorax 7.1%. Kunisaki, 2021, Translational Pediatrics; Ottomeyer et al., 2023, BMC Pediatrics; Nuñez-Paucar et al., 2023, Boletín Médico del Hospital Infantil de México Maternal steroids “have become standard of care” for larger lesions at risk of hydrops; elective resection is commonly recommended, but practice varies (kunisaki2021narrativereviewof pages 1-2, ottomeyer2023earlyresectionof pages 6-7, nunezpaucar2023congenitalpulmonarymalformations pages 4-5)
Trials/registries NCT05701514 (CONNECT): recruiting multicenter RCT; 176 infants; elective surgery at 6–9 months vs watchful waiting; primary endpoint = exercise tolerance at 5 years. NCT03044769: Swiss prospective registry/biobank; longitudinal clinical, imaging, lung function, and biomarker outcomes. NCT01732185: completed basic-science interventional study (n=45) using transcriptomics/proteomics/CGH array on CCAM tissue. NCT04449614: completed retrospective observational cohort (n=72) reviewing thoracoscopic CPAM resection outcomes. ClinicalTrials.gov records: 2023 CONNECT; 2016 Swiss CLA registry; 2012 molecular study; 2018 surgical review CONNECT randomizes asymptomatic infants to “elective surgical resection at 6–9 months or conservative (watchful waiting) management” (NCT05701514 chunk 1, NCT05701514 chunk 2, NCT03044769 chunk 1, NCT01732185 chunk 1, NCT04449614 chunk 1)

Table: This table condenses the highest-yield disease-characteristic facts for congenital pulmonary airway malformation, emphasizing 2023–2024 reviews and studies plus active trial infrastructure. It highlights the quantitative thresholds, molecular discoveries, imaging standards, and unresolved management questions most useful for a knowledge-base entry.

Evidence limitations (for knowledge-base population)

  • Standardized disease identifiers (MONDO/Orphanet/MeSH/ICD/OMIM) were not extractable from the retrieved full texts; populating those fields requires direct queries to the relevant ontology/registry resources.
  • Environmental risk/protective factors, robust QoL metrics, and validated animal models were not identified in the retrieved evidence set.

References

  1. (cancemi2024congenitallungmalformations pages 5-6): Giovanna Cancemi, Giulio Distefano, Gioele Vitaliti, Dario Milazzo, Giuseppe Terzo, Giuseppe Belfiore, Vincenzo Di Benedetto, Maria Grazia Scuderi, Maria Coronella, Andrea Giovanni Musumeci, Daniele Grippaldi, Letizia Antonella Mauro, Pietro Valerio Foti, Antonio Basile, and Stefano Palmucci. Congenital lung malformations: a pictorial review of imaging findings and a practical guide for diagnosis. Children, 11:638, May 2024. URL: https://doi.org/10.3390/children11060638, doi:10.3390/children11060638. This article has 22 citations.

  2. (pederiva2023congenitallungmalformations pages 1-6): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  3. (bertolino2024congenitalpulmonaryairway pages 1-2): Alessia Bertolino, Silvia Bertolo, Paola Lago, and Paola Midrio. Congenital pulmonary airway malformation in preterm infants: a case report and review of the literature. Aug 2024. URL: https://doi.org/10.3390/life14080990, doi:10.3390/life14080990. This article has 6 citations.

  4. (eber2024lungmalformationspredicting pages 1-2): E. Eber. Lung malformations: predicting respiratory distress at birth. Pediatric Respiratory Journal, 02:180, Nov 2024. URL: https://doi.org/10.56164/pediatrrespirj.2024.56, doi:10.56164/pediatrrespirj.2024.56. This article has 0 citations.

  5. (kunisaki2021narrativereviewof pages 1-2): Shaun M. Kunisaki. Narrative review of congenital lung lesions. Translational Pediatrics, 10:1418-1431, May 2021. URL: https://doi.org/10.21037/tp-20-133, doi:10.21037/tp-20-133. This article has 78 citations and is from a peer-reviewed journal.

  6. (NCT05701514 chunk 1): dr. J Marco Schnater. The COllaborative Neonatal Network for the First CPAM Trial. Erasmus Medical Center. 2023. ClinicalTrials.gov Identifier: NCT05701514

  7. (pederiva2023congenitallungmalformations pages 13-16): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  8. (windrich2024rasmapkpathwaymutations pages 1-2): Jonas Windrich, Peter Braubach, Florian Länger, Jens Dingemann, Nicolaus Schwerk, Martin Wetzke, Diane M. Renz, Martin Zenker, Denny Schanze, and Christian P. Kratz. Ras-mapk pathway mutations in congenital pulmonary airway malformations. May 2024. URL: https://doi.org/10.1164/rccm.202311-2163le, doi:10.1164/rccm.202311-2163le. This article has 9 citations and is from a highest quality peer-reviewed journal.

  9. (windrich2024rasmapkpathwaymutations pages 2-3): Jonas Windrich, Peter Braubach, Florian Länger, Jens Dingemann, Nicolaus Schwerk, Martin Wetzke, Diane M. Renz, Martin Zenker, Denny Schanze, and Christian P. Kratz. Ras-mapk pathway mutations in congenital pulmonary airway malformations. May 2024. URL: https://doi.org/10.1164/rccm.202311-2163le, doi:10.1164/rccm.202311-2163le. This article has 9 citations and is from a highest quality peer-reviewed journal.

  10. (windrich2024rasmapkpathwaymutations pages 3-3): Jonas Windrich, Peter Braubach, Florian Länger, Jens Dingemann, Nicolaus Schwerk, Martin Wetzke, Diane M. Renz, Martin Zenker, Denny Schanze, and Christian P. Kratz. Ras-mapk pathway mutations in congenital pulmonary airway malformations. May 2024. URL: https://doi.org/10.1164/rccm.202311-2163le, doi:10.1164/rccm.202311-2163le. This article has 9 citations and is from a highest quality peer-reviewed journal.

  11. (pederiva2023congenitallungmalformations pages 6-9): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  12. (pederiva2023congenitallungmalformations pages 9-13): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  13. (ottomeyer2023earlyresectionof pages 6-7): Megan Ottomeyer, Charles Huddleston, Rachel M. Berkovich, David S. Brink, Joyce M. Koenig, and Kurtis T. Sobush. Early resection of a rare congenital pulmonary airway malformation causing severe progressive respiratory distress in a preterm neonate: a case report and review of the literature. BMC Pediatrics, May 2023. URL: https://doi.org/10.1186/s12887-023-04049-3, doi:10.1186/s12887-023-04049-3. This article has 13 citations and is from a peer-reviewed journal.

  14. (nunezpaucar2023congenitalpulmonarymalformations pages 4-5): Héctor Nuñez-Paucar, Noé Atamari-Anahui, and Carlos Valera-Moreno. Congenital pulmonary malformations in children in a pediatric hospital in peru, 2010-2020. Boletín Médico del Hospital Infantil de México, Sep 2023. URL: https://doi.org/10.24875/bmhim.23000055, doi:10.24875/bmhim.23000055. This article has 2 citations.

  15. (pederiva2023congenitallungmalformations pages 20-24): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  16. (mussi2024respiratoryfollowupin pages 2-3): Nicole Mussi, Erika Maugeri, Michela Deolmi, Alberto Scarpa, Emilio Casolari, Giovanna Pisi, Valentina Fainardi, and Susanna Esposito. Respiratory follow-up in a cohort of children with congenital malformations affecting lung development: a cohort study. International Journal of Pediatrics and Child Health, 12:80-88, Jul 2024. URL: https://doi.org/10.12974/2311-8687.2024.12.11, doi:10.12974/2311-8687.2024.12.11. This article has 0 citations.

  17. (NCT05701514 chunk 2): dr. J Marco Schnater. The COllaborative Neonatal Network for the First CPAM Trial. Erasmus Medical Center. 2023. ClinicalTrials.gov Identifier: NCT05701514

  18. (cancemi2024congenitallungmalformations pages 4-5): Giovanna Cancemi, Giulio Distefano, Gioele Vitaliti, Dario Milazzo, Giuseppe Terzo, Giuseppe Belfiore, Vincenzo Di Benedetto, Maria Grazia Scuderi, Maria Coronella, Andrea Giovanni Musumeci, Daniele Grippaldi, Letizia Antonella Mauro, Pietro Valerio Foti, Antonio Basile, and Stefano Palmucci. Congenital lung malformations: a pictorial review of imaging findings and a practical guide for diagnosis. Children, 11:638, May 2024. URL: https://doi.org/10.3390/children11060638, doi:10.3390/children11060638. This article has 22 citations.

  19. (goli2024earlydetectionand pages 1-2): Yasaman Dasteh Goli and Harsh Datta. Early detection and management of congenital pulmonary airway malformation in a newborn with stable clinical course. Journal of Case Reports and Images in Pediatrics, 6:5-10, Oct 2024. URL: https://doi.org/10.5348/100026z19yg2024cr, doi:10.5348/100026z19yg2024cr. This article has 0 citations.

  20. (pederiva2023congenitallungmalformations pages 16-20): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  21. (kane2020theutilityof pages 1-2): Stefan C. Kane, Emanuele Ancona, Karen L. Reidy, and Ricardo Palma-Dias. The utility of the congenital pulmonary airway malformation-volume ratio in the assessment of fetal echogenic lung lesions: a systematic review. Fetal Diagnosis and Therapy, 47:171-181, Oct 2020. URL: https://doi.org/10.1159/000502841, doi:10.1159/000502841. This article has 43 citations and is from a peer-reviewed journal.

  22. (gonzalez2024congenitalpulmonaryairway pages 4-5): Andrés González and Laura Laverde. Congenital pulmonary airway malformation (cpam). a case report. Medical & Clinical Case Reports Journal, 2:557-562, Nov 2024. URL: https://doi.org/10.51219/mccrj/andres-gonzalez/146, doi:10.51219/mccrj/andres-gonzalez/146. This article has 0 citations.

  23. (bertolino2024congenitalpulmonaryairway pages 2-5): Alessia Bertolino, Silvia Bertolo, Paola Lago, and Paola Midrio. Congenital pulmonary airway malformation in preterm infants: a case report and review of the literature. Aug 2024. URL: https://doi.org/10.3390/life14080990, doi:10.3390/life14080990. This article has 6 citations.

  24. (NCT03044769 chunk 1): Isabelle Ruchonnet-Métrailler. Congenital Lung Anomalies (CLA) Swiss Database. University Hospital, Geneva. 2016. ClinicalTrials.gov Identifier: NCT03044769

  25. (NCT01732185 chunk 1): Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations. Assistance Publique - Hôpitaux de Paris. 2012. ClinicalTrials.gov Identifier: NCT01732185

  26. (NCT04449614 chunk 1): A Review of Surgical Management of Congenital Pulmonary Airway Malformations (CPAM): A Decade of Experience. King's College Hospital NHS Trust. 2018. ClinicalTrials.gov Identifier: NCT04449614

  27. (pederiva2023congenitallungmalformations media 94ace63e): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  28. (pederiva2023congenitallungmalformations media 92254196): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.

  29. (pederiva2023congenitallungmalformations media 769ac597): Federica Pederiva, Steven S. Rothenberg, Nigel Hall, Hanneke Ijsselstijn, Kenneth K. Y. Wong, Jan von der Thüsen, Pierluigi Ciet, Reuven Achiron, Adamo Pio d’Adamo, and J. Marco Schnater. Congenital lung malformations. Nature Reviews Disease Primers, 9:1-16, Nov 2023. URL: https://doi.org/10.1038/s41572-023-00470-1, doi:10.1038/s41572-023-00470-1. This article has 116 citations.